Key result
Minimally invasive AVR cuts blood loss ~131 mL and shortens stays vs conventional surgery despite longer procedures.
Why the study?
The study was conducted to assess the potential benefits of minimally invasive aortic valve replacement compared with conventional aortic valve replacement by examining short-term outcomes.
Does minimally invasive aortic valve replacement improve short-term outcomes compared to conventional aortic valve replacement in patients undergoing AVR?
Meta-Analysis (n=1,303)
Does minimally invasive aortic valve replacement improve short-term outcomes compared to conventional aortic valve replacement in patients undergoing AVR?
Effect estimate: MD -130.58 mL (95% CI -216.34 to -44.82)
Minimally invasive aortic valve replacement is a safe alternative to conventional surgery, offering reduced blood loss and shorter hospital stays without increasing adverse clinical events.
Supports minimally invasive AVR as safe alternative in suitable patients; reinforces Level 1 evidence for its adoption.
Objective: To assess the potential benefits of minimally invasive aortic valve replacement (MIAVR) compared with conventional AVR (CAVR) by examining short-term outcomes. Methods: A systematic search identified randomized trials comparing MIAVR with CAVR. To assess study limitations and quality of evidence, we used the Cochrane Risk of Bias tool and GRADE and performed random-effects meta-analysis. We used meta-regression and sensitivity analysis to explore reasons for diversity. Results: Thirteen studies (1,303 patients) were included. For the comparison of MIAVR and CAVR, the risk of bias was judged low or unclear and the quality of evidence ranged from very low to moderate. No significant difference was observed in mortality, stroke, acute kidney failure, infectious outcomes, cardiac events, intubation time, intensive care unit stay, reoperation for bleeding, and blood transfusions. Blood loss (mean difference [MD] = −130.58 mL, 95% confidence interval [CI] = −216.34 to −44.82, I 2 = 89%) and hospital stay (MD = −0.93 days, 95% CI = −1.62 to −0.23, I 2 = 81%) were lower with MIAVR. There were shorter aortic cross-clamp (MD = 5.99 min, 95% CI = 0.99 to 10.98, I 2 = 93%) and cardiopulmonary bypass (CPB) times (MD = 7.75 min, 95% CI = 0.27 to 15.24, I 2 = 94%) in the CAVR group. In meta-regression analysis, we found that age was the variable with the greatest influence on heterogeneity. Conclusions: MIAVR seems to be an excellent alternative to CAVR, reducing hospital stay and incidence of hemorrhagic events. Despite significantly greater aortic cross-clamp and CPB times with MIAVR, this did not translate into adverse effects, with no changes in the results found with CAVR.
No takes yet. Share an insight, caveat, or question.
Almeida et al. (2022) conducted a meta-analysis in Aortic valve replacement (n=1,303). Minimally invasive aortic valve replacement (MIAVR) vs. Conventional aortic valve replacement (CAVR) was evaluated on Blood loss (MD -130.58 mL, 95% CI -216.34 to -44.82). Minimally invasive aortic valve replacement reduced blood loss (MD -130.58 mL; 95% CI -216.34 to -44.82) and hospital stay compared with conventional surgery, despite longer procedural times.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: